Product Description
Hydroquinone is a topical skin-bleaching agent used in the cosmetic treatment of hyperpigmented skin conditions. Hydroquinone produces reversible lightening of the skin by interfering with melanin production by the melanocytes. Specifically, inhibition of the enzymatic conversion of tyrosine to DOPA (dihydroxyphenylalanine) results in the desired chemical reduction of pigment. Ultimately, this causes a decrease in the number of melanocytes and decreased transfer of melanin leading to lighter skin. (Sourced from: https://www.aocd.org/page/Hydroquinone)
Mechanisms of Action: Melanin Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Brazil | Canada | Chile | Colombia | Dominican Republic | Ecuador | Egypt | Hong Kong | India | Indonesia | Israel | Jordan | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Singapore | Slovenia | Spain | Sri Lanka | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Cynosure
Company Location: WESTFORD MA 01886
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20200866 | P3 |
Not yet recruiting |
Other |
None |